"Incretins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Peptides which stimulate INSULIN release from the PANCREATIC BETA CELLS following oral nutrient ingestion, or postprandially.
| Descriptor ID |
D054795
|
| MeSH Number(s) |
D27.505.696.399.472.580
|
| Concept/Terms |
Incretins- Incretins
- Glucose-Dependent Insulin-Releasing Hormone
- Glucose Dependent Insulin Releasing Hormone
- Hormone, Glucose-Dependent Insulin-Releasing
- Insulin-Releasing Hormone, Glucose-Dependent
- Incretin
Incretin Effect- Incretin Effect
- Effect, Incretin
- Incretin Effects
- Effects, Incretin
|
Below are MeSH descriptors whose meaning is more general than "Incretins".
Below are MeSH descriptors whose meaning is more specific than "Incretins".
This graph shows the total number of publications written about "Incretins" by people in this website by year, and whether "Incretins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2013 | 1 | 1 | 2 |
| 2014 | 2 | 0 | 2 |
| 2016 | 2 | 0 | 2 |
| 2018 | 1 | 0 | 1 |
| 2020 | 2 | 1 | 3 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Incretins" by people in Profiles.
-
Safety and benefit of incretin-based therapies in patients with type 2 diabetes: learnings and reflections. Expert Opin Drug Saf. 2022 03; 21(3):291-293.
-
The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism. Expert Opin Drug Saf. 2021 Nov; 20(11):1309-1315.
-
Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors. Metabolism. 2020 10; 111:154343.
-
Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights. J Cardiovasc Pharmacol Ther. 2020 11; 25(6):494-496.
-
The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes. Metabolism. 2020 08; 109:154295.
-
GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms. Biochim Biophys Acta Mol Basis Dis. 2018 09; 1864(9 Pt B):2814-2821.
-
Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study. Cardiovasc Diabetol. 2016 Dec 03; 15(1):162.
-
Incretins, Pregnancy, and Gestational Diabetes. Curr Pharm Biotechnol. 2016; 17(7):597-602.
-
Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury. Alzheimers Dement. 2014 Feb; 10(1 Suppl):S62-75.
-
Incretin-based therapies, glucometabolic health and endovascular inflammation. Curr Pharm Des. 2014; 20(31):4953-60.